AIM: Hec1, a member of the Ndc80 kinetochore complex, is highly expressed in cancers. The aim of this study was to explore the role and mechanism of action of Hec1 with respect to the cytotoxicity of paclitaxel in ovarian cancer. METHODS: Thirty ovarian cancer samples and 6 normal ovarian samples were collected. Hec1 expression in these samples was determined with immunohistochemistry. Ovarian cancer cell lines A2780, OV2008, C13K, SKOV3, and CAOV3 and A2780/Taxol were examined. Cell apoptosis and cell cycle analysis were detected with flow cytometric technique. siRNA was used to delete Hec1 in the cells. The expression of related mRNAs and proteins was measured using RT-PCR and Western blot analysis, respectively. RESULTS: Hec1 expression was significantly higher in ovarian cancer samples than in normal ovarian samples, and was associated with paclitaxel-resistance and poor prognosis. Among the 6 ovarian cancer cell lines examined, Hec1 expression was highest in paclitaxel-resistant A2780/Taxol cells, and lowest in A2780 cells. Depleting Hec1 in A2780/Taxol cells with siRNA decreased the IC50 value of paclitaxel by more than 10-fold (from 590±26.7 to 45.6±19.4 nmol/L). Depleting Hec1 in A2780 cells had no significant effect on the paclitaxel sensitivity. In paclitaxel-treated A2780/Taxol cells, depleting Hec1 significantly increased the cleaved PARP and Bax protein levels, and decreased the Bcl-xL protein level. CONCLUSION: Hec1 overexpression is associated with the progression and poor prognosis of ovarian cancer. Inhibition of Hec1 expression can sensitize ovarian cancer cells to paclitaxel.
AIM: Hec1, a member of the Ndc80 kinetochore complex, is highly expressed in cancers. The aim of this study was to explore the role and mechanism of action of Hec1 with respect to the cytotoxicity of paclitaxel in ovarian cancer. METHODS: Thirty ovarian cancer samples and 6 normal ovarian samples were collected. Hec1 expression in these samples was determined with immunohistochemistry. Ovarian cancer cell lines A2780, OV2008, C13K, SKOV3, and CAOV3 and A2780/Taxol were examined. Cell apoptosis and cell cycle analysis were detected with flow cytometric technique. siRNA was used to delete Hec1 in the cells. The expression of related mRNAs and proteins was measured using RT-PCR and Western blot analysis, respectively. RESULTS:Hec1 expression was significantly higher in ovarian cancer samples than in normal ovarian samples, and was associated with paclitaxel-resistance and poor prognosis. Among the 6 ovarian cancer cell lines examined, Hec1 expression was highest in paclitaxel-resistant A2780/Taxol cells, and lowest in A2780 cells. Depleting Hec1 in A2780/Taxol cells with siRNA decreased the IC50 value of paclitaxel by more than 10-fold (from 590±26.7 to 45.6±19.4 nmol/L). Depleting Hec1 in A2780 cells had no significant effect on the paclitaxel sensitivity. In paclitaxel-treated A2780/Taxol cells, depleting Hec1 significantly increased the cleaved PARP and Bax protein levels, and decreased the Bcl-xL protein level. CONCLUSION:Hec1 overexpression is associated with the progression and poor prognosis of ovarian cancer. Inhibition of Hec1 expression can sensitize ovarian cancer cells to paclitaxel.
Authors: Li Wang; Fang Yin; Yulei Du; Bei Chen; Shuhui Liang; Yongguo Zhang; Wenqi Du; Kaichun Wu; Jie Ding; Daiming Fan Journal: Tumour Biol Date: 2010-05-04
Authors: Jennifer G DeLuca; Walter E Gall; Claudio Ciferri; Daniela Cimini; Andrea Musacchio; E D Salmon Journal: Cell Date: 2006-12-01 Impact factor: 41.582
Authors: Guikai Wu; Xiao-Long Qiu; Longen Zhou; Jiewen Zhu; Richard Chamberlin; Johnson Lau; Phang-Lang Chen; Wen-Hwa Lee Journal: Cancer Res Date: 2008-10-15 Impact factor: 12.701
Authors: Charles Swanton; Barbara Nicke; Marion Schuett; Aron C Eklund; Charlotte Ng; Qiyuan Li; Thomas Hardcastle; Alvin Lee; Rajat Roy; Philip East; Maik Kschischo; David Endesfelder; Paul Wylie; Se Nyun Kim; Jie-Guang Chen; Michael Howell; Thomas Ried; Jens K Habermann; Gert Auer; James D Brenton; Zoltan Szallasi; Julian Downward Journal: Proc Natl Acad Sci U S A Date: 2009-05-19 Impact factor: 11.205
Authors: Charles Swanton; Michela Marani; Olivier Pardo; Patricia H Warne; Gavin Kelly; Erik Sahai; Frédéric Elustondo; Jenny Chang; Jillian Temple; Ahmed A Ahmed; James D Brenton; Julian Downward; Barbara Nicke Journal: Cancer Cell Date: 2007-06 Impact factor: 31.743
Authors: Melyssa S Roberts; Jennifer M Sahni; Morgan S Schrock; Katrina M Piemonte; Kristen L Weber-Bonk; Darcie D Seachrist; Stefanie Avril; Lindsey J Anstine; Salendra Singh; Steven T Sizemore; Vinay Varadan; Matthew K Summers; Ruth A Keri Journal: Cancer Res Date: 2020-02-13 Impact factor: 12.701
Authors: Leena J Laine; Jenni H E Mäki-Jouppila; Emma Kutvonen; Pekka Tiikkainen; Thomas K M Nyholm; Jerry F Tien; Neil T Umbreit; Ville Härmä; Lila Kallio; Trisha N Davis; Charles L Asbury; Antti Poso; Gary J Gorbsky; Marko J Kallio Journal: Oncoscience Date: 2021-12-10